Cooperative Agreement UG3DA061615
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $680K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Minneapolis, MN 55414, USA
Similar Awards
- The Cooperative Agreement award titled "Applying Neuromodulation to Boost the Efficacy of Motivational Interviewing" is funded by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279). The $899,869 award, effective from September 30, 2025 to August 31, 2027, supports research at the Lovelace Biomedical Research Institute to investigate the use of transcranial alternating current stimulation (tACS) to enhance brain rhythms and...
- This $1,585,991 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a study to evaluate the use of transcranial direct current stimulation (tDCS) combined with cognitive reappraisal training to reduce craving and cue-reactivity in individuals with cocaine use disorder. The study will conduct a double-blind randomized trial with four groups (n=120 total) to assess the synergistic effects of real vs....
- This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
- The National Institute on Drug Abuse (NIDA), through the Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $684,694 Cooperative Agreement to New York University (NYU) to develop and evaluate a novel home-based intervention combining transcranial direct current stimulation (tDCS) with mindfulness meditation for the treatment of cannabis use disorder (CUD). The project, titled "Telehealth-Delivered tDCS for Cannabis Addiction Recovery: The C.A.R.E.S. (Cannabis Addiction...
- This Project Grant award of $398,137 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for developing high-precision epigenetic therapeutics to address the growing opioid use disorder (OUD) epidemic in the United States. The award will enable Boston Interactome LLC to apply a novel approach targeting protein-protein interactions of the neuronal G9A complex, a key regulator of DFosB expression under chronic opioid exposure....
- This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting Mebias Discovery Inc. in the development of a new chemical entity, MEB-1170, for the treatment of opioid use disorder (OUD). The project will complete preclinical studies in rodents and non-human primates to evaluate the efficacy of MEB-1170 as a maintenance medication for OUD, as well as conduct Phase 1 clinical trials to assess the...
- This federal Project Grant award of $798,828.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The key products and services to be delivered include: The development of an AI platform called M3.AI that will integrate target-based and phenotype-based methodologies to efficiently identify new drug candidates for OUD...
- This Cooperative Agreement, awarded by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,664,000.00 in funding to The Washington University to develop negative allosteric modulators (NAMs) of the mu opioid receptor as potential treatments for opioid overdose and opioid use disorder. The key products and services to be delivered through this 2-year award, which runs from September 1, 2025 to August 31, 2027, include...
- This federal Project Grant award of $739,353 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a study to develop an effective and efficient multicomponent intervention to increase buprenorphine treatment retention for individuals with opioid use disorder. The study, titled "BUP - BOOSTER: Behavioral Optimization for Overcoming Suboptimal Treatment Retention," will test the impact of three psychosocial...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the CFDA program "Drug Use and Addiction Research Programs" (93.279), will support research to uncover the neurophysiological signatures within the addiction circuitry related to acute opioid use. The $159,711 award, effective January 1, 2025 through December 31, 2029, will leverage a unique ability to directly record local field potentials from awake humans with implanted brain electrodes. This will...